Author Archives: Marisa Wexler MS

FDA Gives Green Light to Clinical Trial of Zofin

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…

New Therapeutic Target for COPD Identified in Study

Inhibiting a protein called lymphotoxin beta receptor (LTβR) could be an effective therapeutic strategy for chronic obstructive pulmonary disease (COPD), new research suggests. The findings were published in Nature, in the study “Inhibition of LTβR signalling activates WNT-induced regeneration in lung.” COPD is characterized by the…

European CHMP Gives Positive Opinion to COPD Therapy Trixeo Aerosphere

A committee from the European Medicines Agency (EMA) recommended that AstraZeneca‘s triple combination therapy Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) be approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The recommendation, from the EMA’s Committee for Medicinal Products for…

AstraZeneca’s New Data Shows Breztri Aerosphere Better for All Seasons

Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…